Organogenesis Holdings (ORGO) AI Stock Analysis

• Market Cap: $503.84M
• Dividend Yield: N/A
• Average Volume (3M): 1.33M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.37
• Revenue Growth: 2.24%
• EPS Growth: -67.56%
• Country: US
• Employees: 869
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.12
• Shares Outstanding: 126,912,140
• 10 Day Avg. Volume: 897,810
• 30 Day Avg. Volume: 1,334,990
• PEG Ratio: -5.91
• Price to Book (P/B): 1.09
• Price to Sales (P/S): 0.87
• P/FCF Ratio: 100.90
• Enterprise Value/Market Cap: 1.31
• Enterprise Value/Revenue: 1.42
• Enterprise Value/Gross Profit: 1.90
• Enterprise Value/Ebitda: 33.39
• 1Y Price Target: $9.00
• Price Target Upside: 120.59% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): 0.18
• Revenue Forecast (FY): $543.40M

• Rating: 52 Neutral
• Price Target: $4.00 ▼(-1.96% Downside)

Overall score is held back mainly by weak profitability and negative operating/free cash flow despite a strong balance sheet. Recent technicals are moderately supportive, and the latest earnings call showed strong revenue/EBITDA execution and raised guidance, but clinical/regulatory timing issues and the cash decline add meaningful risk. Valuation is also less supportive due to the negative P/E.

Positive Factors

Revenue Growth

Strong revenue growth indicates robust demand for Organogenesis's products, enhancing its competitive position and supporting future expansion.

CMS Policy Favorable for Future Growth

Favorable CMS policy changes enhance market access, potentially increasing sales and supporting long-term growth in the regenerative medicine sector.

FDA Rolling Submission for ReNu

The FDA submission for ReNu could lead to new product approvals, expanding the company's portfolio and addressing significant medical needs, driving future growth.

Negative Factors

Weak Profitability

Weak profitability metrics indicate challenges in cost management and pricing power, potentially impacting long-term financial health and investment capacity.

Cash Position Decline

A significant decline in cash reserves limits financial flexibility, potentially constraining strategic investments and operational resilience.

ReNu Phase III Trial Setback

The setback in ReNu's Phase III trial could delay product launch and revenue generation, impacting long-term growth prospects and competitive positioning.

Organogenesis Holdings Business Overview & Revenue Model

Company Description

Organogenesis Holdings Inc., a regenerative medicine company develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane wound covering in which viable cells growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, and cytokines; NuShield, a wound covering tissue includes both amnion and chorion membranes for spongy/intermediate layer intact; PuraPly , a antimicrobial barrier that enables conformability and fluid drainage; and Novachor, an amniotic membrane wound covering in which viable cells, growth factors/cytokines, and ECM proteins are preserved. Its surgical and sports medicine products comprise NuCel, a dehydrated placental tissue surgically applied to the target tissue to support native healing; ReNu, a cryopreserved suspension used to support healing of soft tissues; and FiberOS and OCMP used as a bone void filler primarily in orthopedic and neurosurgical applications. The company's pipeline products include PuraPly XT and PuraPly MZ to treat chronic, acute, and open wounds; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales force and independent agencies. The company was founded in 1985 and is headquartered in Canton, Massachusetts.

How the Company Makes Money

Organogenesis generates revenue through the sale of its regenerative medicine products, primarily targeting hospitals, clinics, and healthcare providers. The company has established key revenue streams through its advanced wound care products, which include Apligraf and Dermagraft, as well as its surgical biologics line. Additionally, Organogenesis benefits from partnerships with healthcare facilities and providers, which help to expand its market reach and facilitate the adoption of its products. The company also engages in ongoing research and development to innovate and introduce new products, further supporting its revenue growth.

Organogenesis Holdings Financial Statement Overview

Summary

Organogenesis Holdings faces challenges in profitability and cash flow management, despite maintaining a solid balance sheet with low leverage. The income statement shows mixed performance with slight revenue growth but negative net profit and EBIT margins. The cash flow analysis reveals significant challenges with negative operating and free cash flow, despite a positive growth rate. Overall, the company needs to improve operational efficiency and cash flow generation.

Income Statement

Organogenesis Holdings shows a mixed performance in its income statement. The TTM (Trailing-Twelve-Months) data indicates a slight revenue growth of 8.31%, but the company struggles with profitability, as evidenced by a negative net profit margin of -1.89% and an EBIT margin of -5.90%. The gross profit margin remains relatively healthy at 48.43%, suggesting some operational efficiency. However, the declining EBITDA margin to 0.74% highlights challenges in managing operating expenses.

Balance Sheet

The balance sheet reflects a stable financial position with a low debt-to-equity ratio of 0.16, indicating conservative leverage. However, the return on equity is negative at -2.57%, pointing to inefficiencies in generating returns for shareholders. The equity ratio of 75.71% suggests a strong capital structure with significant equity backing.

Cash Flow

Cash flow analysis reveals significant challenges, with negative operating cash flow and free cash flow in the TTM period. Despite a positive free cash flow growth rate of 11.39%, the operating cash flow to net income ratio is -0.43, indicating cash flow issues relative to earnings. The free cash flow to net income ratio of 1.33 suggests reliance on non-operating sources for cash generation.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	464.99M	482.04M	433.14M	450.89M	467.36M	338.30M
Gross Profit	346.34M	366.30M	326.66M	345.87M	353.16M	250.98M
EBITDA	19.75M	15.76M	36.03M	40.32M	87.00M	37.23M
Net Income	1.00M	861.00K	4.95M	15.53M	94.20M	17.23M
Balance Sheet
Total Assets	509.83M	497.89M	460.02M	449.36M	443.26M	290.22M
Cash, Cash Equivalents and Short-Term Investments	64.37M	135.57M	104.34M	102.48M	113.93M	84.39M
Total Debt	40.81M	43.31M	119.35M	123.79M	132.30M	84.77M
Total Liabilities	123.85M	112.57M	181.36M	183.69M	201.92M	148.41M
Stockholders Equity	385.98M	385.32M	278.66M	265.67M	241.34M	141.81M
Cash Flow
Free Cash Flow	-51.65M	4.18M	6.55M	-9.04M	30.76M	-12.21M
Operating Cash Flow	-38.79M	14.21M	30.92M	24.86M	61.98M	5.47M
Investing Cash Flow	-12.86M	-10.03M	-24.36M	-33.90M	-31.22M	-23.50M
Financing Cash Flow	21.10M	27.64M	-5.50M	-2.20M	-1.04M	42.47M

Organogenesis Holdings Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 4.08
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ORGO, the sentiment is Negative. The current price of 4.08 is below the 20-day moving average (MA) of 4.86, below the 50-day MA of 5.07, and below the 200-day MA of 4.40, indicating a bearish trend. The MACD of -0.31 indicates Positive momentum. The RSI at 30.90 is Neutral, neither overbought nor oversold. The STOCH value of 7.66 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ORGO.

Organogenesis Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SIGA	77 Outperform	$473.35M	6.32	39.94%	―	-0.85%	-13.50%
EBS	59 Neutral	$575.09M	8.49	13.92%	―	-29.91%	―
ORGO	52 Neutral	$503.84M	-38.63	0.30%	―	2.24%	-67.56%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
EOLS	50 Neutral	$324.10M	-5.70	―	―	15.10%	0.18%
SNDL	48 Neutral	$417.15M	-6.40	-7.82%	―	1.76%	18.31%
ESPR	46 Neutral	$748.27M	-5.67	―	―	2.83%	13.61%

Organogenesis Holdings Corporate Events

Organogenesis Extends Long-Term Leases for Key Facilities

On December 22, 2025, Organogenesis Inc. amended its leases for two key facilities at 65 Dan Road and 150 Dan Road in Canton, Massachusetts, extending the terms from their current expiration date of December 31, 2027 to December 31, 2032, with an additional two-year renewal option through December 31, 2034. The amendments lock in a rent structure tied to at least 103% of the 2027 annual rents, with potential adjustments to fair market value and 3% annual increases, formalizing long-term control over critical manufacturing, logistics, and R&D space. Because the properties are owned, directly or indirectly, by major shareholders and a sitting director, the transactions were reviewed as related-party dealings; the company’s Audit Committee concluded the lease amendments were fair, reasonable, and in the best interests of the company and its stockholders, potentially reducing governance risk around these arrangements.

The most recent analyst rating on (ORGO) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Organogenesis Holdings stock, see the ORGO Stock Forecast page.